Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Next Previous
Trial Profile

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Hyponatraemia
  • Focus Pharmacodynamics
  • Acronyms SAND

    • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Aug 2018 to 1 Apr 2019.
    • 06 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
    • 25 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top